Migraine with aura from pathophysiology to treatment: therapeutic strategies.
Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.
D'Andrea
G
G
Headache and Cerebrovascular Center, Villa Margherita Neurological Clinic, Arcugnano VI, Italy. giovinavi@libero.it
Allais
G
G
Grazzi
L
L
Fumagalli
L
L
D004827:Epilepsy / Q000503:physiopathology; D006801:Humans; D020325:Migraine with Aura / Q000503:physiopathology* / Q000628:therapy*